Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma

Authors:	M. Dror Michaelson MD PhD Rana R. McKay MD Lillian Werner MS Michael B. Atkins MD Eliezer M. Van Allen MD Kara M. Olivier NP Jiaxi Song BS Sabina Signoretti MD David F. McDermott MD Toni K. Choueiri MD

Affiliation:	1. Massachusetts General Hospital Cancer Center, Boston, Massachusetts;2. Kidney Cancer Center, The Lank Center for Genitourinary Oncology, Dana‐Farber Cancer Institute, Boston, Massachusetts;3. Department of Biostatistics and Computational Biology, Dana‐Farber Cancer Institute, Boston, Massachusetts;4. Department of Medical Oncology, Georgetown‐Lombardi Comprehensive Cancer Center, Washington, DC;5. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts;6. Department of Medical Oncology, Beth‐Israel Deaconess Medical Center, Boston, Massachusetts

Abstract:

Keywords:	chemotherapy poor risk renal cell carcinoma sarcomatoid vascular endothelial growth factor (VEGF) targeted